Shmuel Cabilly

Medasense Biometrics Ltd. develops pain monitoring devices. The firm is a medical device company that develops a continuous and non-invasive pain-monitoring device. The company was founded by Galit Zuckerman and Itay Goor-Aryeh in 2008 and is headquartered in Ramat Yishai, Israel.

Oplon BV develops antimicrobial coating technology for packaging, pads and devices. It offers protective products, coatings and processes based on a novel polymer compound, which prevent the colonization of microbes by creating a protective physical shield on surfaces. The firm’s products are used by beverages, fresh meat and dairy markets. The company was founded in 2006 by Shmuel Bukshpan and Uriel Halavee and is headquartered in Delft, the Netherlands.

Pixcell Medical Technologies Ltd. develops, produces, and markets portable medical diagnostic products for point of care testing. Its product is HemoScreen. The company was founded by Max Herzberg and Avishay Bransky on June 3, 2008 and is headquartered in Yokneam Ilit, Israel.

DiA Imaging Analysis Ltd. operates as an imaging processing software company. It technology is based on a platform of proprietary algorithms that enable automatic detection of the heart’s ventricle walls borders. The firm’s platform enables the evaluation of echo images to be fully automated. The company was founded in 2009 and is headquartered in Be'er Sheva, Israel.

Treato Ltd. provides social health patient intelligence solutions. Its patient intelligence platform offers both patients and healthcare stakeholders insights based on the aggregated wisdom of the crowd through its free patient site, treato.com, and its professional service offering, Treato Pharma. The company was founded by Gideon Mantel, Itzchak Lichtenfeld, and Jacob Sabo in 2007 and is headquartered in Yehud, Israel.

Ornim Medical Ltd. provides medical devices and monitering tools. The company is headquartered in Kfar Saba, Israel.

Vidac Pharma Ltd. manufactures pharmaceutical products. It is a clinical stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. The company was founded in 2011 by Max Herzberg is headquartered in Jerusalem, Israel.

Silenseed Ltd. operates as a biopharmaceutical company. Its programs include SiG12D-LODER for pancreatic cancer, and Prostate-LODER, GBM-LODER for brain cancer. The company was founded by Dr. Amotz Shemi and Prof. Eithan Galun on November 30, 2008 and is headquartered in Modi’in, Israel.

Efranat Ltd. develops anti-cancer immunotherapy treatment. Its product is based on a natural plasma glycoprotein molecule that activates the innate immune system against cancer. The company was founded by Boaz Shoham, Nobuto Yamamoto and Avi Levin in 2009 and is headquartered in Rehovot, Israel.

Pango Mobile Parking Ltd. provides parking payment and management system solutions. It offers mobile parking solutions and systems, location based services and mobile parking. The company was founded in 1995 and is headquartered in Kadima, Israel.

Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel.

Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012.

Next Dimension Ltd. develops retinal imaging systems. Its products are used for diagnosis and monitoring the treatment of vision threatening diseases and to measure the quantity of oxygen in different areas of retina cells. The company was founded in 2006 by Sara Krupsky, David Rosenblatt and Marek Sternheim and is headquartered in Ofakim, Israel.